Other VSMC-specific targets, including transcription factor 21, hyaluronan synthase 3, KLF4, growth differentiation factor 10, and NOTCH, offer potential therapeutic avenues for atherosclerosis, including in diabetes [187]. This evidence concerns the gene KLF4 and diabetes mellitus.